Blockbuster Biologics Review, produced by our Intellectual Property lawyers, covers developments in inter partes review (IPR) and patent litigation challenges to blockbuster biologic drugs.
These quarterly reports provide updates on the following topics:
- The current status of IPR challenges to blockbuster biologics
- The institution and invalidation rates for IPRs challenging blockbuster biologics
- The current status of patent litigations implicating blockbuster biologics
We will continue to monitor developments and provide updates regularly.
Issue 5 (April 2019) >>
Issue 4 (January 2019) >>
Issue 3 (October 2018) >>
Issue 2 (July 2018) >>
Issue 1 (April 2018) >>